共 63 条
[1]
De G. M.(1995)Binding of valsartan to mammalian AT Regul Pept 59 303-11
[2]
Whitebread S.(1994) receptors Eur J Clin Pharmacol 47 231-45
[3]
Mueller P.(1993)Angiotensin II receptor blocakade with single doses of valsartan in healthy, normotensive subjects Br J Pharmacol 110 761-71
[4]
Cohen T.(1998)Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the Ang II AT1-receptor subtype Clin Ther 20 1106-14
[5]
de Gasparo M.(1997)Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker Eur J Clin Pharmacol 52 451-9
[6]
Criscone L.(1998)Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol J Hum Hypertens 12 861-6
[7]
de Gasparo M.(1997)Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing therapy with monotherapy Drugs 54 299-311
[8]
Bühlmayer P.(1996)Valsartan. A review of its pharmacology and therapeutic use in essential hypertension Clin Ther 18 797-810
[9]
Pool J.(1997)The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension Eur J Clin Pharmacol 52 173-7
[10]
Oparil S.(1998)Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide Circulation 98 2037-42